Vancouver, British Columbia – January 25, 2016 – Sirona Biochem Corp. (TSX-V: SBM / FSE: ZSB), announces that it has been chosen for a second time, by the Consulate General of Canada, to present at the Dose of the Valley conference on February 9 - 10 in San Francisco, California.br>
Sirona’s Chief Business Development Officer, Attila Hajdu, will communicate the current state of the Company’s pipeline and future strategy in addition to participating in follow up meetings with key investors and leading companies in the pharmaceutical and cosmetic industries. The Canadian Technology Accelerator program is a new conference feature this year that identifies areas of potential collaboration for Sirona’s platform technology of fluorination chemistry.br>
“We are extremely happy to be invited back to the Dose of the Valley and look forward to exploring new growth opportunities” said Attila Hajdu, Chief Business Development Officer of Sirona Biochem. “Sirona has an innovative platform technology that can be applied to develop new compounds in areas of unmet needs, and we have already begun to explore strategic partnerships with big pharma to unlock the potential value in new opportunities.”
About Dose of the Valley
The two-day program organized by the C100 (www.thec100.org), BDC Venture Capital (www.bdc.ca) and the San Francisco Consulate is designed to connect Canada’s most promising biopharma, medical device, and health IT companies with key players from within the Bay Area and Silicon Valley. Dose of the Valley will facilitate face-to-face interaction with investors, technology scouts, mentors, and industry experts. The program provides an opportunity to gain visibility and develop productive relationships within this vibrant ecosystem.
San Francisco and the Silicon Valley represent a global hub for life sciences. With a significant presence of pharmaceutical companies, health care providers, and venture capital, this region holds tremendous opportunity for Canadian companies. Applications for participation will be evaluated based on stage of development, industry validation, and relevancy to local industry interests. Elements of this program will be built to reflect the corporate objectives and therapeutic focus of participating companies.
